Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1992-3-10
|
| pubmed:abstractText |
Forty-nine patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) were treated with 3 cycles of induction chemotherapy prior to definitive local treatment (surgery and/or radiation therapy). Chemotherapy consisted of carboplatin 300 mg/m2 on day 1, fluorouracil 1000 mg/m2 daily as a continuous infusion on days 1 to 5 and high-dose methotrexate 1.2 g/m2 with leucovorin rescue on day 14. After completing the induction chemotherapy, 9 patients (18%) achieved a complete remission (CR), 26 (54%) a partial remission (PR), 7 had stable disease and 7 a progression. The response rates increased to 53% CR and 18% PR following locoregional treatment. Survival at 12 months was 61% and its actuarial probability at 24 months 31%. Median time to progression was 14 months. Toxicity from chemotherapy was generally mild. Nausea was observed in 35%, vomiting in 26%, stomatitis in 57%, anemia in 22%, leukopenia in 36%, thrombocytopenia in 26% and diarrhea in 6% of the patients. In conclusion, the combination of carboplatin, 5-day continuous-infusion fluorouracil and mid-cycle high-dose methotrexate is a moderately effective, well tolerated regimen in patients with SCCHN but does not seem superior to the combination of carboplatin and fluorouracil only.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0300-8916
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
31
|
| pubmed:volume |
77
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
426-31
|
| pubmed:dateRevised |
2008-12-12
|
| pubmed:meshHeading |
pubmed-meshheading:1781038-Aged,
pubmed-meshheading:1781038-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1781038-Carboplatin,
pubmed-meshheading:1781038-Combined Modality Therapy,
pubmed-meshheading:1781038-Drug Administration Schedule,
pubmed-meshheading:1781038-Female,
pubmed-meshheading:1781038-Fluorouracil,
pubmed-meshheading:1781038-Head and Neck Neoplasms,
pubmed-meshheading:1781038-Humans,
pubmed-meshheading:1781038-Male,
pubmed-meshheading:1781038-Methotrexate,
pubmed-meshheading:1781038-Middle Aged,
pubmed-meshheading:1781038-Neoplasm Staging,
pubmed-meshheading:1781038-Radiotherapy Dosage,
pubmed-meshheading:1781038-Remission Induction,
pubmed-meshheading:1781038-Survival Analysis
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Carboplatin, continuous infusion fluorouracil and mid-cycle high-dose methotrexate as initial treatment in patients with locally advanced head and neck cancer. Hellenic Co-operative Oncology Group Study.
|
| pubmed:affiliation |
Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece.
|
| pubmed:publicationType |
Journal Article
|